© 2020 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
ASCO
Flatiron Health's Bobby Green Outlines Cancer Clinical Trial to Understand Genomic Changes in Tumors (Pt. 4)
June 22, 2020
During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.
Sharpless:10,000 Excess Breast, Colorectal Cancers Deaths This Decade From Deferred Care Related to COVID-19
June 20, 2020
The "conservative estimate" assumes that disruption of services ends in six months.
Flatiron Health’s Dr. Bobby Green Outlines Novel Clinical Trial to Understand Genomic Changes in Tumors (pt. 2) (VIDEO)
June 06, 2020
During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials.
Kathi Mooney of Huntsman Cancer Institute Speaks on Hospital-at-Home Programs
June 03, 2020
Kathi Mooney, Ph.D., RN, FAAN, interim senior director of population sciences at the Huntsman Cancer Institute in Salt Lake City, discusses hospital-at-home programs and how they are common in countries with single-payer systems and include patients with conditions ranging from cellulitis to heart failure. The benefits include the familiarity of home surroundings, avoidance of hospital-acquired infection, and less de-conditioning from being in a hospital bed.
Jeffrey Skolnik of Inovio Pharmaceuticals Inc. Discusses Glioblastoma Treatment
June 02, 2020
Jeffrey Skolnik, MD, vice president, clinical development of Inovio Pharmaceuticals Inc Discusses Glioblastoma Treatment in ASCO interview.
AstraZeneca's Adrian Kilcoyne Claims Paradigm Shift in Lung Cancer Treatment
June 02, 2020
Adrian Kilcoyne MD MBA MPH, vice president, US Medical Affairs and HEOR, oncology, AstraZeneca, discusses a paradigm shift in lung cancer treatment due to the overwhelming efficacy of the EGFR-TKI treatment.
AstraZeneca’s Tagrisso Keeps Most Lung Cancer Patients With Mutation Alive Two Years After Surgery
June 01, 2020
Tagrisso, the targeted therapy made by AstraZeneca, could become the treatment of choice for the majority of lung cancer patients with mutations in a certain gene who are treated after surgery, based on findings presented this past weekend at the American Society of Clinical Oncology annual meeting.